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HIGHLIGHTS 
 Cationic state of the Dox in NLCs determined drug release and in vitro efficacy 
 NLCs with cationic and neutral Dox were loaded into bacterial cellulose (BC)  
 The hybrid BC-NCL-NH system was efficacious inhibiting tumor growth and metastasis 
 BC-NLCs-NH eradicated the side effects of intratumorally administered Dox 
 
Abstract 
 
The use of hybrid materials, where a matrix sustains nanoparticles controlling the release of the 
chemotherapeutic drug, could be beneficial for the treatment of primary tumors prior or after 
surgery. This localized chemotherapy would guarantee high drug concentrations at the tumor site 
while precluding systemic drug exposure minimizing undesirable side effects.  
We combined bacterial cellulose hydrogel (BC) and nanostructured lipid carriers (NLCs) 
including doxorubicin (Dox) as a drug model. NLCs loaded with cationic Dox (NLCs-H) or 
neutral Dox (NLCs-N) were fully characterized and their cell internalization and cytotoxic 
efficacy were evaluated in vitro against MDA-MB-231 cells. Thereafter, a fixed combination of 
NLCs-H and NLCs-N loaded into BC (BC-NLCs-NH) was assayed in vivo into an orthotopic 
breast cancer mouse model.  
NLCs-H showed low encapsulation efficiency (48%) and fast release of the drug while NLCs-N 
showed higher encapsulation (97%) and sustained drug release. Both NLCs internalized via 
endocytic pathway, while allowing a sustained release of the Dox, which in turn rendered IC50 
values below of those of free Dox. Taking advantage of the differential drug release, a mixture 
of NLCs-N and NLCs-H was encapsulated into BC matrix (BC-NLCs-NH) and assayed in vivo, 
showing a significant reduction of tumor growth, metastasis incidence and local drug toxicities.  
 
Keywords: Drug delivery, bacterial cellulose, nanostructured lipid carriers, doxorubicin, breast 
cancer, localized chemotherapy, nanocomposite, neo-adjuvant therapy, hydrogel, controlled 
release.  
 
1. INTRODUCTION 
Cancer is the second worldwide cause of mortality accounting for 8.2 million deaths in 2012 [1]. 
Even though surgical tumor resection is the preferred treatment for solid localized tumors at early 
or intermediate stage, radiation and/or chemotherapy therapies are often employed to prevent 
recurrent tumor grow [2]. However, tumor location, size and stage may preclude this surgical 
approach in many patients dramatically reducing their survival [3]. Additionally, diffusion and 
efficacy of therapeutic drugs are far from optimal. Drug molecules injected systemically must 
travel longer distances from blood vessels to reach tumor cells (≥ 100 µm) compared with normal 
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tissues, and consequently, there is insufficient drug concentration and penetration at the tumor 
site [4]. Moreover, only about 10% to 15% of tumor cells population are expected to be within 
the mitotic phase of cell division when the drug reaches the tumor and therefore, its antitumor 
effect is often limited by the short circulation half-life of chemotherapeutic drugs [2,5,6]. In 
addition, surpassing multidrug resistance (MDR) is also a big challenge in chemotherapeutic 
treatments. MDR can be acquired during treatment due to an adaptive response of cancer cells to 
cytotoxic drugs, leading to treatment failure [7,8]. Therefore, high doses of chemotherapeutic 
agents are required, which further turns into drug-related toxicity [9]. In this sense, localized 
sustained release of chemotherapeutics could improve the treatments by ensuring an extended 
local exposure of tumor cells to drugs, while lowering systemic drug levels [10].  
Biomaterials have been thoroughly investigated as platforms for efficient drug encapsulation and 
sustained release at the implantation site of localized chemotherapy [11]. Localized 
chemotherapy allows high drug concentrations at the tumor site for extended periods of time 
while keeping low systemic drug exposure. The potential advantages of local therapy are the 
reduction of undesirable side effects in the patients and lowering the chance of acquiring drug 
resistance in the long term [3]. Additionally, this treatment schemes reduce the need for repeated 
drug administrations. The implantation of this devise works as an adjuvant therapy, being 
possible to combine it with low-doses systemic administration of common chemotherapeutics 
[11]. Particularly, hydrogels are hydrophilic polymeric networks with tissue-like properties and 
applications on tissue engineering and drug delivery [12,13]. Among biopolymers, bacterial 
cellulose (BC) has been extensively studied [14]. BC is an extra-cellular polysaccharide 
synthesized in Gram-negative bacteria, like Komagataeibacter hansenii, and located at the 
interface of air/liquid culture. This cellulose is synthesized in nanofibrils composed of β-1→4 
glucose units stabilized by inter- and intra-chain hydrogen bonds. BC hydrogels with 
nanofibrillar structure are composed of pure cellulose network containing more than 90% water, 
possess high mechanical strength and thermostability, and well-defined biocompatibility 
[15],[16]. Further, high flexibility and porosity (i.e. similar to collagen) makes BC an excellent 
biomaterial that could be used as matrix for localized drug delivery [14]. Moreover, BC can be 
purified reaching endotoxin values lower than 20 endotoxin units/device and is already approved 
by the FDA for implants [17]. Nevertheless, low molecular weight molecules can diffuse freely 
in and out of the BC membranes which results in undesirable burst release of most drugs [15].  
On the other hand, drug delivery nanosystems have been widely developed in the last years 
aiming the improvement of the therapeutic index of marketed drugs by means of modifying their 
pharmacokinetics and biodistribution [18],[19]. Additionally, nanoparticle-based drug delivery 
systems could overcome drug resistance using a Trojan horse-like approach [7] to bypass the 
effect of the MDR machinery such as efflux pumps [20,21]. Among lipid nanosystems, 
nanostructured lipid carriers (NLCs) are a second generation of solid lipid nanoparticles evolved 
to improve some drawbacks such as close-fitting packaging among lipid molecules. This 
decreases the encapsulation efficiency (EE) of cargo molecules which are often extruded from 
the high crystalline structure of the nanoparticle. NLCs are composed by a mixture of solid and 
liquid lipids which generate imperfections within the matrix, decreasing its crystallinity and 
facilitating the accommodation of drug molecules. In this sense, improved drug encapsulation, 
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minimized drug leakage during storage and controlled drug release kinetics are expected [22,23]. 
Additional advantages of NCL include high biocompatibility and simple production at large scale 
[24]. NLCs have been gaining attention for delivery of commonly used chemotherapeutics such 
as doxorubicin (Dox) and cisplatin [25–27]. Moreover, lipid based nanocarriers have been 
described as valuable devices for drug delivery systems to overcome MDR in cancer cells [28–
31]. 
The integration of both structures, BC and NLC, might help to develop hierarchical implantable 
matrices taking advantage of the positive role of each system. Once nanoparticles are embedded 
into a hydrogel a unique hybrid biomaterial is synthesized that could show extended drug release. 
Also, BC-NLC hybrid hydrogels can combine the properties of fast release of the free drug 
dispersed into polymeric network and long-term molecular release from the drug-loaded 
nanoparticles [12]. The relevance of using combinations of BC and nanoparticle has been 
recently highlighted in the work of Chu et al. where bacterial cellulose was used as a depot for 
C60 nanoparticles, an effective photosensitizer for photodynamic therapy in skin cancer [32].  
In the present work, a novel hybrid biomaterial combining bacterial cellulose hydrogel and lipid 
nanoparticles was developed for its application as local drug delivery implant for cancer therapy 
using Dox. NLCs loaded with two forms of Dox were analyzed in vitro and in vivo using MDA-
MB-231 breast cancer cell line and an orthotopic mouse model. In our hands, BC-NLCs-NH 
showed low levels of local and systemic toxicity as well as strong efficacy in tumor reduction 
and metastatic incidence. These results clearly reinforce the potential use of BC-NLCs-NH as 
local drug delivery system.  
 
2. EXPERIMENTAL SECTION 
2.1. Materials 
The lipid myristyl myristate (Crodamol™ MM) and the oil (Crodamol™ GTCC-LQ) were kindly 
donated by Croda (Argentina). Doxorubicin hydrocloride (Dox, MW 579.98) was kindly 
supplied by LKM pharmaceuticals (Argentina). 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and Pluronic®F68 were provided by Sigma-Aldrich (St. 
Louis, Mo, USA). All other reagents used were of analytical or microbiological grade purchased 
from Sigma-Aldrich or Merck (Darmstadt, Germany). 
2.2. Nanostructured lipid carrier (NLC) preparation  
NLCs containing Dox were prepared by sonication method [33]. Briefly, 400 mg of solid lipid 
(2.0%, w/v) were melted under water bath at 60°C and mixed with 10 mg of Dox (dissolved in 
100 µL of DMSO). Liquid lipid (oil) (0.06%, v/v) was incorporated. After 10 min, a hot aqueous 
solution (20 mL) containing 3% (w/v) of Pluronic®F68 was added to the lipid phase. 
Immediately, the mixture was sonicated for 50 min (40% amplitude) using an ultrasonic 
processor (130 Watts, Cole-Parmer, USA) equipped with 3 mm titanium tip. Then, the dispersion 
was cooled at room temperature and stored at 5°C. 
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Two forms of Dox were used to prepare the NLCs. First, 10 mg/mL Dox hydrochloride was 
solubilized in 1.0 mM HCl solution (pH= 3.0, favoring dominance of the cationic drug, hereafter 
called Dox-H) and incorporated to NLCs (NLCs-H). Alternatively, the pH of a Dox solution was 
adjusted to 8.5 (hereafter called Dox-N). The ionic equilibrium of Dox is dynamic under the 
experimental conditions because is involved in several types of molecular interactions such as 
- stacking of the aromatic rings at high concentrations. Dox dimerization constant (Kd) 
depends directly on total drug concentration [34]. Moreover, after increasing the pH at 8.5, drug 
solubility decrease is considerable (from 20 mg/ml to 0,3 mg/ml) [35]. Consequently, equilibrium 
is displaced to the predominant form of neutral Dox in solution. Then, the solution was frozen at 
-80ºC and lyophilized. The Dox-N was used to prepare the NLC formulation (NLCs-N) using 
the same lipid composition as NLCs-H.  
2.3. Measurement of free Dox and Dox loading efficiency in NLCs 
After NLCs synthesis, the final reaction volume was measured (evaporation occurred during 
sonication procedure). Samples of 500 µL were then transferred to ultrafiltration centrifugal 
device (MWCO 10,000, Microcon, Millipore, MA, USA) and centrifuged at 5,000 ×g for 10 min 
to retain the NLCs. The filtrate was 10-times diluted in 10 mM phosphate buffer to measure the 
non-encapsulated Dox by fluorimetry (PerkinElmer LS 50B, Japan). The encapsulation 
efficiency (EE) was calculated as follows:  
𝐸𝐸 (%)  =
(𝑄𝑜 − (𝐶𝑟 𝑥 𝑉)) 𝑋 100
𝑄𝑜
 
Where, Qo is initial amount of Dox, Cr is concentration of Dox in the filtered solution, and V is 
the final volume after finishing the preparation. 
Additionally, the total amount of Dox in each formulation was analyzed. First, 450 µL of 
methanol was added to 100 µL of NLCs. Then, 450 µL of chloroform was incorporated and 
centrifuged at 10,000 ×g for 10 min. The supernatant was diluted 10-times with a 
methanol/chloroform mixture (50:50) and the total Dox was measured.  
Dox was quantified by fluorimetry using λex= 476 nm and λem= 588 nm, according the appropriate 
calibration curve in the range of 2.5 to 12.5 µM. 
2.4. Particle size, zeta potential and poly-dispersity index (PDI) 
The average diameter and size distribution of lipid nanoparticles were measured by photon 
correlation spectroscopy (PCS) (Nano ZS Zetasizer, Malvern Instruments Corp, UK) at 25ºC in 
polystyrene cuvettes with a thickness of 10 mm. The zeta potential was determined by laser 
Doppler anemometry also using the Nano ZS Zetasizer. The zeta potential measurements were 
performed in capillary cells, for the NPs dispersed in deionized water obtained from Milli-Q 
system (Millipore, MA, USA). Also, the PDI value was determined. All the measurements were 
carried out in triplicate. 
2.5. Drug release assays  
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Experiments were performed using dialysis membranes (MWCO 10 kDa.). The membranes were 
soaked with distilled water for 12 h and filled with 5.0 mL of each formulation of NLCs, followed 
by immersion in 30 mL of 10 mM acetate buffer (pH= 5.0) or 10 mM phosphate buffer (pH= 
7.4) at 37°C, with continuous shaking at 200 rpm. At different times, samples of 10 mL were 
withdrawn and Dox concentration was measured in a fluorimeter, as explained above.  
2.6. Physicochemical characterizations  
2.6.1. Thermogravimetric analysis (TGA) 
Dynamic thermogravimetric measurements of the nanoparticles were performed by using a 
Shimadzu TGA-50 instrument (Tokyo, Japan). Tests were run in the range of 0ºC to 600ºC at a 
heating rate of 10ºC/min under N2 atmosphere.  
2.6.2. Differential scanning calorimetry (DSC) 
Thermal properties of NLCs particles were determined by differential scanning calorimetry 
(DSC, PerkinElmer Inc., Model Pyris 1, Waltham, MA, USA) under nitrogen atmosphere. Scans 
were carried out at a heating rate of 10ºC min-1 in the 20ºC - 240ºC temperature range.  
2.6.3. X-ray Diffraction analysis (XRD) 
XRD patterns were collected in reflection mode on a glass substrate, and analyzed by Origin and 
Sigma Plot software. The measurement was performed with an Analytical Expert instrument 
using Cu-Kα radiation (λ= 1.54 Å) from 2θ= 10º to 60º in continuous mode with 0.07º step size. 
Scattering angles were transformed into short spacing using Bragg’s equation: 2d (sin Ө) = n λ. 
2.7. Microscopic studies 
2.7.1. Scanning electron microscopy (SEM) 
Samples were placed in glass slides and dried by the critic point technique. After that, the surface 
was sputtered with gold using a metalizer (BalzersSCD 030), obtaining a layer thickness in the 
range of 15 to 20 nm. Film surfaces and morphologies were observed by SEM (Philips SEM 505 
model, Rochester, NY, USA). The images were processed by an image digitizer program (Soft 
Imaging System ADDA II).  
2.7.2. Transmission electron microscopy (TEM) 
The nanoparticle dispersion was 10-times diluted with ultrapure water and a drop of the 
dispersion was spread onto a collodion-coated Cu grid (400-mesh). Liquid excess was drained 
with paper filter (Whatman #1) and for contrast enhancement a drop of phosphotungstic acid as 
added to the NLCs dispersion. Finally, TEM analysis was performed using Jeol-1200 EX II-TEM 
microscope (Jeol, MA, USA). 
2.8. In vitro assays  
2.8.1. Cell culture 
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Breast cancer cell line MDA-MB-231 was obtained from the American Type Culture Collection 
(ATCC® HTB-26™, LGC Standards, Barcelona, Spain), and cultured in Dulbecco's modified 
Eagle's medium (DMEM/F12; Invitrogen, Paisley, UK) supplemented with 10% fetal bovine 
serum (FBS; Lonza, Barcelona, Spain), 1% penicillin-streptomycin, 1% L-Glutamine, 1% non-
essential amino acids and 1% sodium pyruvate (Life Technologies, Madrid, Spain). Cells were 
maintained in an atmosphere with 5% CO2 and 95% humidified atmosphere air at 37°C.  
2.8.2. Internalization assay  
Cells were seed for 24 h in standard 24-well plates at 8×104 cells per well to test the free Dox 
internalization kinetic, NLCs-N and NLCs-H. It was used an equivalent Dox concentration of 
0.625 µM. After drug exposition for 0.5, 1, 2, 3 and 6 h cells were washed twice with PBS. Then, 
were treated with trypsin and 1.0 mL of medium was added to each well. After that, samples 
were collected in cytometry tubes and centrifuged at 2500 xg for 5 min. Supernatant was 
discarded and cells were re-suspended in 350 µL of PBS. Fluorescence intensity was monitored 
using a FACSCalibur (Becton–Dickinson, Franklin Lakes, NJ, USA) and analyzed using FCS 
Express 3.0 software (De Novo Software, Los Angeles, CA, USA). 
2.8.3. Cytotoxicity tests 
Cytotoxicity of NLC samples were performed in MDA-MB-231 cells seeded for 24 h in standard 
96-well plates at 6×103 cells per well. Cells were treated for 72 h with medium containing 
different Dox equivalent concentrations (0.0061–100 µM) of the following compounds: free 
Dox, NLCs-N and NLCs-H. After the incubation, cells were washed with PBS and fresh medium 
added. Cell viability was determined using a tetrazolium dye (MTT) assay as previously 
described [36]. Briefly, cells were incubated for 4 h containing 0.5 g L-1 of MTT, and the medium 
replaced with DMSO to dissolve the formazan crystals formed by viable cells. Absorbance was 
measured at 540 nm using a multi-well plate reader (ELX800, Biotek, France). The inhibitory 
concentration (IC50) was determined as the drug concentration that resulted in a 50% reduction 
in cell viability after fitting a dose response curve (GraphPad Prism 6 software, San Diego, CA, 
USA). Results were expressed as a mean of three independent experiments. 
2.8.4. Confocal microscopy 
MDA-MB-231 cells were plated in collagen-coated cover glasses on 24 well-plates at density of 
100,000 cells mL-1 of DMEM/F12 with 10% FBS and incubated at 37ºC for 24 h. Thereafter, 
cells were exposed to free Dox and NLCs-N at a concentration of 10 µM. After 2 h incubation, 
medium was discharged and cells were washed with PBS. Next, Lysotracker Green (20 µM, 
Invitrogen, MA, USA) was added to each well and incubated at 37ºC for 30 min. Cells were 
washed and counterstained with Hoechst 33342 (Sigma-Aldrich, MO, USA) prior to their 
visualization by confocal laser scanning microscope (Olympus FV1000 Confocal and Spectral 
Microscope, Japan). 
2.8.5. Fluorescence confocal spectral imaging (FCSI) 
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MDA-MB-231 cells adherent to poly-D-lysine coated cover glasses were grown in 24-well plates 
and incubated with NLCs-N at 1.0 µM Dox for 1 h or 22 h. After washing them three times with 
fresh PBS, the cover glasses were placed between a microscope slide and a cover slip to be 
scanned for FCSI using a LabRAM laser scanning confocal microspectrometer (Horiba, 
Villeneuve d’Ascq, France), equipped with a 300 ‘/mm diffraction grating and a CCD detector 
air-cooled by Peltier effect. The Dox fluorescence was excited using 491 nm line of a solid laser 
(Cobolt, model Calypso 75), under a long focal microscope objective 50×. The equatorial optical 
section of each selected cell was scanned with a step of 0.8 m and the full fluorescence spectrum 
has been recorded for each scanned point (typically 30×30 = 900 spectra per cell optical section). 
The laser light power at the sample was ca. 0.2 mW and the acquisition time was 0.05 sec per 
spectrum. Both acquisition and treatment of spectral maps were performed using LabSpec 
software. The spectral maps were generated as described elsewhere [37]. Briefly, each 
fluorescence spectrum has been fitted with a proportional sum of model spectra characteristic of 
subcellular locations and/or interactions. The fitting coefficients were used to generate the 
corresponding spectral maps shown with pseudo colors. 
2.9. Preparation of the biopolymeric matrix: NLCs loading and release 
The synthesis of bacterial cellulose (BC) by K. hansenii (ATCC 23769) was performed in a 
medium containing (g L-1): 25.0 mannitol, 5.0 yeast extract, 3.0 peptone, and adjusted to pH 6.5 
with 100 mM NaOH solution before sterilization. The culture was maintained statically in 48-
well plates at 30ºC for 10 days. The BC films were collected from the plates and washed with 
distilled water. BC purification was performed incubating the membranes in 100 mM NaOH at 
50ºC for 24 h followed by successive washes with distilled water, thereafter the pH was adjusted 
to 7.0. Later, the BC films were sterilized by autoclaving (121ºC for 20 min). Next, BC films 
were loaded with free Dox (BC-Dox), NLCs-N (BC-NLCs-N) and a mix of NLCs-N and NLCs-
H in a 20:80 ratio (BC-NLCs-NH), respectively.  
Loading assays of BC films were performed by immersion in the corresponding 1.0 mM Dox 
solutions. After 24 h incubation, the films were washed with physiologic solution followed by 
Dox extraction using organic solvents. First, BC films were immersed in methanol for 2 h 
followed by an immersion in methanol/chloroform (50:50) for another 2 h. Finally, one more 
methanol immersion was performed for 2 h. Total Dox was quantified by fluorimetry. 
Dox kinetic release from BC loaded films was analyzed by soaking the films into 2 mL-tubes 
containing 1.5 mL of physiologic solution at 37ºC. Samples of 200 µL were taken out from the 
tubes at different times and Dox was quantified by fluorescence. The assays were performed by 
quadruplicate for 35 days and results expressed as a mean of two independent experiments.  
2.10. In vivo tumorigenic assays 
Female athymic nude mice (Envigo Crs. S.A., Barcelona, Spain) were kept in pathogen-free 
conditions and used at 7 weeks of age. Animal care was handled in accordance with the Guide 
for the Care and Use of Laboratory Animals of the Vall d´Hebron University Hospital Animal 
Facility, and the experimental procedures were approved by the Animal Experimentation Ethical 
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Committee at the institution. In vivo studies were performed by the ICTS “NANBIOSIS”, at the 
CIBER-BBN’s in vivo Experimental Platform of the Functional Validation & Preclinical 
Research (FVPR) area (http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/) 
(Barcelona, Spain). 
MDA-MB-231.Fluc cells (2 ×106) suspended in 200 μL of PBS with Matrigel (1:1) (BD 
Bioscience, Bedford, MA, USA) were implanted into the right abdominal mammary fat pad 
(i.m.f.p.). Tumor growth was monitored twice a week by conventional caliper measurements 
(D×d2/2, where D is the major diameter and d the minor diameter). After sixteen days post-tumor 
inoculation, a circular BC film (= 12 mm) loaded with a mix of NLCs-N and NLCs-H in a 
20:80 ratio (BC-NLCs-NH), respectively, and containing a Dox loading of 0.14 mg was placed 
at the primary tumor site during a second surgery that placed the film between the tumor-bearing 
mammary fat pad and the abdominal wall. The control groups consisted of a free Dox 
intratumorally injected group (0.14 mg in 25 µL as a unique dose) and a non-treated one (n= 
9/group). During treatment, supervision of the animals and body weight measurement were 
performed twice a week. Clinical observations included changes in skin, eyes, mucous 
membranes, alterations in respiratory pattern, behavior, posture, response to handling and the 
presence of abnormal movements. At the end of experiment, primary tumors, lungs and heart 
were excised and weighted. Tissues were cleaned with PBS, fixed in 4% formaldehyde solution 
and embedded in paraffin. 
2.11. Statistical analysis 
Statistical analyses and graphs were performed using GraphPad Prism 6 software. If not said 
otherwise, all error bars in figures correspond to standard deviation (SD) The significance 
threshold was established at p<0.05, and significance levels were schematically assigned *(0.01 
≤ p < 0.05), **(0.001 ≤ p < 0.01) or ***(0.0001 ≤ p < 0.001).  
 
3. RESULTS AND DISCUSSION 
3.1. NLCs synthesis and characterization 
Colloidal drug delivery system based on NLC was selected as a suitable Dox carrier. 
Encapsulation was performed considering the different ionic states of the anthracycline in 
equilibrium and the predominance of each form depending on the surrounding pH (Scheme 1) 
[38]. Once Dox hydrochloride was solubilized, the molecule exists as a monocation (Dox-H). 
The specific pKa for Dox primary amine deprotonation is 8.46 [38,39]. During encapsulation 
experiments, the residual charge of Dox could determine the interaction within the matrix 
components and probably determine the drug release kinetic. In this sense, there were obtained 
two forms of the drug: the monocation (Dox-H) and a predominance of neutral Dox species (Dox-
N) by adjusting the pH solution (Scheme 1). Later, both forms of Dox were incorporated in the 
lipid phase and by ultra-sonication method two NLCs formulations with different characteristics 
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were observed, named NCL-H or NCL-N depending on their cargo, Dox-H or Dox-N, 
respectively.  
Dox EE showed significant differences between the NLC-H and NLC-N formulations (Table 1). 
NLCs synthesis containing Dox-N exhibited a high EE (96.6%), due to the more hydrophobic 
character of both matrix and drug. On the other hand, NLCs-H synthesis produced a two times 
decrease on EE (value of 48.0%) which points out that 52% of Dox-H was not encapsulated and 
remains free in the formulation. 
Analysis of both types of NLC by DLS and zeta potential confirmed similar values of around 
150 nm for hydrodynamic diameter and +2.5 mV for the surface charge (Table 1). The size and 
the slightly positive charge of the nanoparticles suggested good properties for cell internalization 
[40]. Further, polydispersity (PDI) values indicate a nearly mono-dispersed nanoparticles 
suspension for both systems with a very uniform size distribution (Table 1 and Figure S1). These 
results suggest that the difference on Dox charge (Dox-H or Dox-N) does not interfere with NLCs 
size and morphology. 
 
Morphology and size distribution of NLCs were also studied by TEM microscopy (Figures 1A 
& 1B). Images showed a pretty narrow size-distribution of nanoparticles with spherical shape 
and mean diameters below 150 nm, either for NLCs-N and NLCs-H in agreement with DLS 
experiments (Table 1). TGA analysis of NLCs has been depicted showing the TGA derivative 
(DTGA) curves (Figure 1C) or the original TGA curves (Figure S2B). DTGA gave specific 
information about the inflexions found in decomposition thermograms (Figure 1C). In this sense, 
a strong inflexion at 187ºC was noticed. This temperature value corresponded to Dox melting 
temperature, also confirmed by DSC analysis (Figure S2A). The thermograms (DTGA) showed 
shifts on two peaks, especially one in the range 200ºC - 300ºC which could be attributed to 
myristyl myristate decomposition [41], suggesting that the second step at 398.7ºC observed on 
TGA curves correspond to oil decomposition temperature (Figure S2B). These results confirm 
the presence of two components, lipid and oil, in the nanoparticles. Both NLCs-N and NLCs-H 
exhibited a shift from 398.7ºC to 385.0ºC in comparison with empty NLCs. No peak 
corresponding to Dox melting was observed neither for NLCs-N nor NLCs-H. Moreover, the 
shifted peak at 245ºC in NLCs-N DTGA suggested the presence of two peaks which could be 
attributed to the overlap of Dox and the lipid peaks. Thermal analyses clearly indicated the 
existence of strong interactions between the lipid components and the Dox, especially for NLCs-
N.  
The crystalline structure of NLCs and the polymorphism of the lipid matrix were analyzed by 
XRD (Figure 1D). Drugs have the propensity to exhibit different molecular arrangements in 
nanocarrier lattices [42]. Analysis of the crystalline structure of Dox and NLCs can help to 
optimize formulation. Moreover, it has been also reported that crystalline structure of lipids have 
strong effects on drug EE and controlled release kinetic [43,44]. Fats can crystallize in three main 
polymorphic forms, in which the α form is unstable, the β is the most stable and the β´ a 
metastable form, still possesses disorders regions and maintains a partial amorphous state [45]. 
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NLCs showed a mixture of polymorphisms characterized by short spacing (d) obtained from 
XRD patterns. “d” corresponds to the distance due to lateral packing of the fatty acid chains on 
the triacylglycerol molecules [46]. NLCs patterns displayed characteristic short spacing at 
0.47/0.38/0.37 nm (typical of the β modification) and 0.42/0.38 nm (β´ form) [45]. Dox 
diffractogram exposed the presence of three peaks (2ϴ= 28.47º, 31.81º and 45.58º) suggesting 
the existence of Dox crystals on its pure form [47]. On the other hand, NLCs diffractogram 
showed the corresponding peaks to myristyl myristate (2θ= 19.11°, 21.59°, 23.23° and 23.80°), 
as previously reported [41]. When NLCs were loaded with Dox the XRD patterns exhibited peaks 
at similar scattered 2ϴ angles of 18.66º, 20.94º, 22.75º and 23.50º for NLCs-N and 19.18º, 21.51º, 
23.32º and 23.80º for NLCs-H. The fusion of the last two peaks suggests the predominance of β´ 
architecture in both NLCs. NLCs-N showed a decrease on the intensity of 23.50º peak and an 
increase on peak at 22.75º. This result indicates partial transition of the NLCs structure from a 
more stable form (β) to the metastable polymorphism (β´). The more stable the crystal structure, 
the more organized the molecules will be within the lattice, allowing a better release of the 
entrapped compounds [46,48]. Thus, the predominance of the metastable polymorphism it is 
always preferred for sustained drug release.  
While morphology, size and surface charge remain almost without changes for both 
formulations, structural differences were found. Changes on nanostructure suggested that NLCs 
could work differently as drug delivery systems. At this point, a very simple approach has been 
developed to produce two chemotherapeutic nanoformulations with different properties and 
capabilities.  
3.2. Drug release from NLCs 
Drug release studies were performed to evaluate the capability of NLCs of providing Dox 
sustained release. Figure 2 showed the hyperbolic curves for Dox released from NLCs after five 
days incubation. The dependence of drug release with pH was assayed at pH 7.4 and 5.0 which 
simulates physiologic environment and the acidic conditions for cell internalization by endocytic 
pathway respectively [49]. All kinetics showed an initial Dox burst release, followed by a 
decrease of the drug releasing rate. Significant differences were found between the amount of 
Dox released from NLCs-H and NLCs-N at both pHs (p≤ 0.05). One of the factors affecting the 
initial burst for NLCs-H was the presence of non-encapsulated Dox in the formulation. NLCs-H 
showed high release rate reaching the 100% at pH 5.0 and 66% at pH 7.4 after 5 days. In contrast, 
NLCs-N displayed high capacity to retain Dox and very slow release could be observed. The 
corresponding drug release kinetic showed to be similar to a zero order profile. After 5 days, 80% 
to 90% of the total Dox payload was still entrapped into NLCs-N. These differences could be 
explained by the hydrophilic and hydrophobic nature of each form of Dox. This data agreed with 
the analysis obtained from XRD patterns. NLCs-H showed high structural stability and therefore 
more prone to expel the drug. It was also relevant to observe the pH dependence of the release 
[50]. In both systems, Dox release increased around 1.5 times when pH turn from neutral to acidic 
values, which is a powerful tool regarding active targeting therapies using tumor-specific pH-
responsive nanocarriers [51]. Both NLCs systems provide different Dox release patterns, but 
NLCs behavior under the tested pHs can be predicted independently of the residual charge of 
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Dox. As described before, nanoformulations with different release properties allow to being 
capable to design variable mixtures between both types of NLCs for combinatorial therapy 
approaches. Here, in a novel approach two Dox nanoformulations were developed with different 
properties, leaving open the possibility to their use as a combinatorial therapy using the same 
active principle. This approach could be helping to generate personalized medicine tools where 
therapy can be customized according to the disease profile of each patient.   
3.3 Cell internalization 
Images (Figure 3) showed that free Dox internalized and quickly concentrated at cell nucleus 
(co-stained with Hoechst) after 2 h incubation, while Dox fluorescence associated to NLCs-N 
only appeared in specific zones of the cell cytoplasm, co-stained with Lysotracker green. It is 
worth mentioning that Dox is a small molecule (Mw= 543.5 g mol-1) and internalizes by simple 
passive transport (diffusion) [52]. In contrast, molecules of high molecular weight and 
macromolecular structures (like nanoparticles) are usually internalized by active transport such 
as endocytosis [53]. Moreover, Dox intercalates between DNA base pairs preventing DNA 
replication and therefore, its main action takes place within the nucleus [54]. Indeed, images of 
cells confirmed the presence of free Dox localized within the nucleus, while Dox from NLCs-N 
were located inside lysosomes.  
Subsequently, the molecular state of Dox released from NLCs inside the cell was followed by 
fluorescence confocal spectral imaging (FCSI). FCSI technique is based on the full fluorescence 
spectra of Dox measured at different cell points and provides valuable information about the 
molecular state of the drug once internalized into the cell. Furthermore, analysis on Dox species 
was focused in the nucleus and in the cytoplasm (Figure 4). Cells were incubated for 1 and 22 h 
with the nanoparticles. In Figure 4A two different spectral profiles are shown, one corresponding 
to the cytoplasmic region (blue spectrum in Figure 4A, blue zone in Figure 4B and blue bar in 
Figure 4C) and the other to the nuclear region (red spectrum in Figure 4A, red zone in Figure 
4B and red bar in Figure 4C). Dox fluorescence spectra of these two intracellular locations are 
significantly different from that observed with NLCs-N suspension in PBS (Figure 4A, green 
spectrum and green bars in Figure 4C). The cytosolic spectra showed an increase on the left 
shoulder which is characteristic of Dox fluorescence when the molecule is in low polarity 
environments like cytosolic membrane-enriched organelles such as endosomes and lysosomes 
[55,56]. The nuclear Dox spectra were shifted to a high wavelength because of the drug 
intercalation between base pairs of DNA [55]. In fact, no Dox was found in the nucleus after 1 h 
incubation of the cells with the NLCs. However, nuclear Dox fluorescence relative fraction 
significantly increased after 22 h (red bar in Figure 4C), indicating that Dox was finally released 
from NCLs accumulated in lysosomes and capable to penetrate the nucleus. The overall 
intracellular drug fluorescence was also increased. 
Cell internalization of NLCs-H and NLC-N was compared also by flow cytometry after 6 h 
incubation (Figure S3). As expected, results showed that NLCs-H internalized much better than 
NLCs-N, as rate reflected by higher Dox fluorescence values in the former nanoparticles. Overall 
internalization assays by either confocal microcopy or flow cytometry support the idea that 
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NCLs-N had been slowly internalized into MDA-MB-231 breast cancer cells, mainly through 
the endocytic pathway. These results are advantageous for cancer treatment since they exhibited 
the property of the developed nanoformulation to bypasses the resistance mechanism of cancer 
cells such as efflux pumps [20].  
3.4. In vitro efficacy of NLCs 
The ability of NLCs loaded with both species of Dox to decrease cell viability was tested using 
metastatic breast cancer cell line MDA-MB-231. MDA-MB-231 cells correspond to an 
aggressive, invasive and poorly differentiated human breast cancer cell line with mesenchymal 
phenotype. Further, MDA-MB-231 is a Dox resistant cell line, meaning that higher doses of the 
drug are required to kill these cells [57]. The half maximal inhibitory concentration (IC50) of Dox 
was determined by MTT assays after incubation with free Dox, NLCs-H and NLCs-N at 
equivalent Dox concentrations (Figure 5). The IC50 values for free Dox (24.32 ± 1.21 µM) were 
reduced in NLCs-N (2.17 ± 0.42 µM) and NLC-H (1.28 ± 0.33 µM) indicating that the efficacy 
of the Dox was improved by the use of nanostructured lipids as drug carriers. Even though cell 
internalization process was slower for NLCs, the sustained release of the drug in nanostructured 
lipids increased the efficacy of the free drug. Among both NLCs, the NLCs-H showed better 
results than NLCs-N after 72 h incubation, probably because NLCs-H internalized faster in cells 
and showed a quicker drug release profile than NLCs-N. On the other hand, and as expected, 
unloaded NLCs exhibited no cytotoxicity after 72 h incubation, indicating that the drug carrier 
was innocuous to the cells at the concentrations equivalent to those used for NLCs-H and NLCs-
N. 
3.5. NLCs encapsulation into BC matrix 
Dox loaded NLCs were entrapped into BC films with the aim of generate a polymeric system for 
local drug delivery. BC alone was not suitable to entrap small molecules like Dox as previously 
reported [15,58]. Here, we suggest that the encapsulation of Dox into a hydrophobic nanocarrier 
followed by the loading into BC films to improve drug’s EE and release profile. The procedure 
involves the immersion of films into free Dox (BC-Dox), NLCs-N (BC-NLCs-N) and mixed 
NLCs-H/NLCs-N (BC-NLCs-NH) solutions with equivalent Dox concentration of 1.0 mM. Free 
Dox was encapsulated in low amounts into BC while NLCs increased more than twice Dox EE 
(Table 2). Particularly, NLCs-N generated the highest Dox EE values. The presence of non-
encapsulated Dox in NLCs-H formulation could be contributing to lower EE in NLCs mixture. 
In both cases, it was remarkable that the amount of Dox equivalent payload within NLCs was in 
the same range than Dox doses administrated in previously reported in vivo experiments using 
free Dox or Dox containing materials [59–61].  
 
Drug’s release profiles (Figure 6) showed that BC-Dox released almost all its payload during 
the first 24 h. On the opposite, BC-NLCs-N showed extended and sustained release with only 
22% Dox release after two weeks. Dox release from BC-NLCs-NH was 53% in 14 days. 
Therefore, in the BC-NLCs-NH mixture, NLCs-H exhibited more quickly Dox release, allowing 
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a strong burst release at initial times, while NLCs-N guaranteed a prolonged and sustained release 
of the drug. Since both types of NLCs can be mixed at different proportions to modulate release 
kinetics, there were tested different NLCs ratios to establish proper conditions for in vivo Dox 
dosage. In this case, 80/20 NLCs-H/NLCs-N ratio was established as the best formulation, with 
a release of the 50% of the payload after 24 h (Figure 6). At this point, Dox concentrations 
reached levels comparable to those previously reported in in vivo breast cancer models [62–64]. 
Moreover, after the first 24 h, the released drug amount was sustained in time.   
SEM images showed NLCs entrapped inside the polymeric network and fused to the cellulose 
fibers (Figure 7A & 7B). Additionally, TEM observations of the supernatants from release 
assays were performed to verify the presence of nanoparticles. Images showed NLCs released 
from the BC matrix with conserved spherical morphology (Figure 7C & 7D). The novel 
nanoparticle-hydrogel matrix showed the excellence of integrating a bacterial cellulose network 
and a lipid nanoformulation in a platform easy to produce and handle. In one hand, BC was 
obtained by a simple and environmentally friendly process, and has a very high biocompatibility. 
On the other hand, NLCs formulation showed therapeutic advantages in comparison with free 
Dox, envisioning a potential synergism with the combined use of BC and NLC in vivo.  
3.6. In vivo antitumor efficacy and tolerability of BC-NLCs-NH films 
The use of nanomaterials as drug releasing platforms for localized treatment of tumors has long 
attracted the attention of research scientists [59,61], as a way to control tumor growth or local 
relapses in unresectable tumors and resectable tumors, respectively. To determine the efficacy 
and tolerability of BC-NLCs-NH films, MDA-MB-231 cells were implanted i.m.f.p. into nude 
mice and 16 days post-tumor inoculation, 0.14 mg Dox equivalent/mouse treatment was applied 
by BC-NLCs-NH implantation or intratumoral administration of free Dox.  Since the objective 
of the study was to determine the advantages of using BC-NLCs-NH hybrid system in the local 
treatment of tumors, we did not include any systemic treatment with Dox, whose toxicities and 
tumor inhibiting capabilities have been widely described in the literature [54,59,60,65,66]. Plain 
BC was not considered as a control group either because its biocompatibility has been well-
reported previously [67–70]. Indeed, as a preparatory training exercise, before implanting Dox 
loaded matrices into immunodeficient mice, we also tested the implantation of circular matrices 
(= 12 mm) subcutaneously in the rear flank of immunocompetent C57Bl6 mice (n=3). One 
week after implantation, animals showed no weight loss or distress symptoms, nor there were 
locals signs of inflammation, necrosis or cellular atypia.  
Figure 8A shows the comparative analysis of the antitumoral activity of BC-NLCs-NH and free 
Dox determined as tumor volume in vivo. Both, BC-NLCs-NH and free Dox induced a significant 
delay in tumor growth compared to non-treated controls. Importantly, BC-NLCs-NH could reach 
free Dox range of tumor response. At 36 days after treatment initiation, animals were euthanized 
and primary tumors were removed (Figure 8B). In vivo, at the time of euthanasia, tumor volumes 
in BC-NLCs-NH treated mice were significantly smaller than in non-treated animals (t Student, 
p=0.0025), being this difference higher than in the free Dox group (t Student, p=0.0082). Ex vivo, 
tumor volume values confirmed the above results, showing smaller tumors for BC-NLCs-NH 
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treated mice (t Student vs. control, p=0.0061), compared to those with intratumoral 
administration of free Dox (t Student vs. control, p=0.0123). Indeed, Tumor to control (T/C) 
ratios of tumor volume ex vivo for BC-NLCs-NH and free Dox were 53% and 66%, respectively, 
whereas tumor weight ex vivo was 62% and 81%, respectively.  
Although these treatments were thought for a localized treatment of primary tumors, it is also 
interesting to evaluate the effect of the treatments in the metastatic process, because inhibition of 
the primary tumor growth by these type of treatments might well reduce the large number of cells 
that primary tumors are continuously shedding to the circulation [71,72]. In our case, metastatic 
lesions at the mammary chain (loco-regional dissemination), lumbar lymph nodes (lymphatic 
dissemination) and lung (hematologic dissemination) were detected only in non-treated control 
mice (Sup. Table 1), indicating that BC-NLCs-NH was effective inhibiting the metastatic process 
by controlling the growth of the primary tumor.  
Besides antitumoral activity, toxicity was also determined by monitoring the animal’s body 
weight (T/C ratio), eating and physical activity parameters. Body weight of the animals treated 
with BC-NLCs-NH and free Dox was maintained along the treatment time and no changes in 
eating, drinking, grooming, exploratory behavior, activity, and neurological status were 
observed. However, for free Dox treated animals, inflammation at the tumor site was observed 
the first 20 days after treatment (38% of the animals), and tumor external necrosis was induced 
(63% of the animals) (Table 3). On the contrary, implantation of BC-NLCs-NH system into 
tumor site did not induce inflammation or external tumor necrosis in any case. Moreover, heart 
weight was also studied to examine Dox-associated toxicities, as previously observed after 
repeated systemic administrations of Dox [54,59]. Intratumoral Dox administration or tumor 
implantation of the films prevented Dox release at high doses to systemic circulation, avoiding 
such toxicities. Thus, BC-NLCs-NH reached free Dox range tumor response while diminishing 
Dox-related toxicities.  
To the best of our knowledge, the potentiality of bacterial cellulose as hydrogel for local cancer 
therapy was never reported nor it was tested the combination of bacterial cellulose matrix with 
lipidic nanocarriers in vivo. Overall, our results show that the therapeutic index of Dox can be 
improved when the drug, locally administrated, is entrapped inside a polymeric matrix and 
released in a sustained way. It has been already reported that prolonged exposure of low-dose 
chemotherapy is clinically beneficial [73,74] as it might happen with BC-NLCs-NH. Indeed, a 
potential limitation of the current study is that since animals were euthanized before BC-NLCs-
NH could release all its content, the therapeutic potential of the BC-NLCs-NH in terms of 
increased efficacy has not been completely exploited. However, moved by the positive results in 
terms of safety of the initial BC-NLCs-NH system, we are currently evaluating different ways to 
increase the antitumor effect of the BC matrix. One of the strategies employed in this 
optimization process includes the functionalization of NLCs with targeting molecules that 
facilitate cell internalization. 
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4. CONCLUSIONS 
In summary, we here present a novel hydrogel-nanoparticle hybrid system for localized cancer 
treatment, combining the use of bacterial cellulose matrix with lipidic nanocarriers (NLCs). To 
the best of our knowledge this is the first work describing the use of bacterial cellulose as an 
implantable matrix for local chemotherapy in cancer.  
We demonstrated that NLCs loaded with cationic or neutral forms of Dox exhibited different 
release profiles and that the integration of both NLCs systems in a unique formulation allowed 
combining both release kinetics for a more efficient drug exposition. In vitro experiments 
established that NLCs are internalized into cells by the endocytic pathway, leading to potentially 
overcome MDR mechanisms, while the sustained release of the drug from nanostructured 
particles allowed an increased efficacy over the free Dox. Based on these in vitro results, a drug 
delivery device with a mixed NLCs formulation loaded into BC membranes (BC-NLCS-NH) 
was designed and tested in vivo in an orthotopic breast cancer tumor model. Tumors treated with 
BC-NLCs-NH showed a very significant tumor growth delay, even better than the intratumorally 
administered Dox, but without the side effects such as edema, inflammation and necrosis 
observed in free-Dox treated mice.  
In short, our experimental evidences confirmed that BC-NLCs-NH hydrogel-nanoparticle hybrid 
system could be easily implanted for local treatment of tumors as a neo-adjuvant therapy. As a 
device, this hybrid system facilitates the delivery and accumulation of chemotherapeutic 
nanoparticles into the tumor site, promoting the efficacy of released drug against cancer cells and 
reducing therapeutic undesirable side effects of the free drugs.  
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Figures captions 
Figure 1. TEM, thermogravimetric and XRD analysis of NLCs. TEM images were taken at 
60,000x from NLCs-N (A) and NLCs-H (B). DTGA curves from the TGA analysis (C) and XRD 
patterns (D) of pure Dox, NLCs, NLCs-H and NLCs-N were also studied. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
  26 
Figure 2. Dox released from the NLCs. Drug released was studied at pH 7.4 (10 mM PBS 
buffer) and 5.0 (10 mM acetate buffer) (○ NLCs-N, pH 5.0; ● NLCs-N, pH 7.4; ∆ NLCs-H, pH 
5.0; ▼ NLCs-H, pH 5.0). The results are the mean of two individual experiments, each one 
performed in duplicate, and the errors were calculated by standard deviation. 
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Figure 3. Internalization of NLCs-N in MDA-MB-231 cells. Confocal images of Dox and 
NLCs-N show that free Dox rapidly reaches the nuclei of cells co-stained with Hoechst, whereas 
NLCs-N internalize through the endocytic pathways as shown by the co-localization of the Dox 
signal with the lysosomes (co-stained with Lysotracker green and shown with arrows). 
Magnification bars corresponds to 10 µm and applies to all images.  
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Figure 4. FCSI studies showing the molecular state of Dox delivered by NLCs-N. (A) 
Characteristic of fluorescence spectra of Dox in initial NLCs-N suspension in PBS (green), in 
cellular nucleus (red) and cytosol (blue). (B) Examples of subcellular distribution of the Dox 
fluorescence in MDA-MB-231 cancer cells after 1 or 22 h incubation with NLCs-N. Dashed lines 
show the nucleus limits. (C) Quantitation of the intracellular Dox fluorescence as averaged from 
several spectral maps (n= 10) at 1 or 22 h incubation. 
 
Figure 5. In vitro efficacy of Dox loaded NLCs. Cytotoxicity of free Dox, NLCs-H and NLCs-
N after 72 h incubation was measured by MTT. Results are the mean of three independent 
experiments, and error estimated by standard error of the mean. 
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Figure 6. Dox released from drug or NLCs loaded BC films. Release studies were performed 
at pH 7.4 and 37ºC in PBS. Results correspond to the mean between three individual experiments, 
each performed in duplicate, and error was calculated by standard deviation.  
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Figure 7. Microscopy studies for BC-NLCs-NH. SEM images were taken at 5,000x (A) and 
10,000x (B). TEM images from BC-NLCs-NH supernatant at 50,000x (C) and 100,000x (D). 
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Figure 8. Tumor growth delay induced by BC-NLCs-NH. Comparative analysis of the 
localized i.m.f.p. growth of the MDA-MB-231 BCa cells treated locally with a BC film loaded 
with a mix of NLCs-N:NLCs-H (20:80) (BC-NLCs-NH) containing 0.14 mg of Dox or free Dox 
(0.14 mg as a unique dose given intratumoraly) in athymic nude mice. (A) Conventional 
measurements of tumor volume over time, and (B) individual tumor volu me at end point along 
with representative tumor photographs ex vivo.  
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Scheme 1. Different states of Dox. Dox hydrochloride solubilization and ionic equilibrium 
between Dox mono-cation (Dox-H) and neutral Dox (Dox-N), pKa= 8.46.  
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Table 1. NLCs encapsulation efficiency (EE) and characterization by zeta potential (ζ pot), 
mean diameter and PDI analysis. Results correspond to the mean between three independent 
experiments, each one made in triplicates. 
Formulation 
Size 
(d, nm) 
ζ pot 
(mV) 
PDI 
EE 
(%) 
NLCs-N 154.3±9.5 +2.33±0.06 0.21±0.043 96.60±0.10 
NLCs-H 143.4±1.5 +2.64±0.91 0.170±0.015 48.06±2.68 
 
 
Table 2. Encapsulation efficiency (EE) for loaded BC films, expressed as encapsulated Dox 
in µmol per BC film. Results are the mean of two independent experiments, each one performed 
in quadruplicate, and errors estimated by standard deviation. 
System EE (µmol/film) 
BC-Dox 0.043 ± 0.005 
BC-NLCs-N 0.147 ± 0.014 
BC-NLCs-NH 0.105 ± 0.015 
 
Table 3. Treatment toxicity. Macroscopic observations on tumor site after treatment with free 
Dox and BC-NLCs-NH films. Inflammation and external necrosis were marked as toxicity 
incidences.  
 Free Dox BC-NLCs-NH 
Inflammation 38% 0% 
External necrosis 68% 0% 
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